To determine whether AKT activity is required for chemotherapeutic drug-induced expression of HIF-1α and ACE2, we first treated parental breast cancer cells with the AKT inhibitor MK-2206 to determine the expression of AKT and HIF-1α and ACE2. The gene discussed is HIF1A; the disease is breast cancer.